期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 41, 期 9, 页码 598-610出版社
CELL PRESS
DOI: 10.1016/j.tips.2020.07.003
关键词
-
资金
- Biotechnology and Biological Sciences Research Council [BB/L01923X/1]
- Tenovus Scotland [T17/14]
- Cancer Research UK [C20953/A18644]
- Autonomous Community of Madrid [B2017/BMD-3827]
- Tatiana de Guzman el Bueno Foundation [P-024-FTPGB 2018]
- European Regional Development Fund, Competitiveness Operational Program 2014-2020 (REDBRAIN) [P_37_732/2016]
- BBSRC [BB/L01923X/1] Funding Source: UKRI
Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentation. We propose that a multifaceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) can be deployed against the virus. The strategy provides robust cytoprotection by restoring redox and protein homeostasis, promoting resolu-tion of inflammation, and facilitating repair. NRF2 activators such as sulforaph-ane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well -documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据